Source:http://linkedlifedata.com/resource/pubmed/id/20703257
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2010-10-13
|
| pubmed:abstractText |
We analyzed 368 chronic lymphocytic leukemia patients who underwent allogeneic hematopoietic stem cell transplantation reported to the EBMT registry between 1995 and 2007. There were 198 human leukocyte antigen (HLA)-identical siblings; among unrelated transplants, 31 were well matched in high resolution ('well matched' unrelated donor, WMUD), and 139 were mismatched (MM), including 30 matched in low resolution; 266 patients (72%) received reduced-intensity conditioning and 102 (28%) received standard. According to the EBMT risk score, 11% were in scores 1-3, 23% in score 4, 40% in score 5, 22% in score 6 and 4% in score 7. There was no difference in overall survival (OS) at 5 years between HLA-identical siblings (55% (48-64)) and WMUD (59% (41-84)), P=0.82. In contrast, OS was significantly worse for MM (37% (29-48) P=0.005) due to a significant excess of transplant-related mortality. Also OS worsened significantly when EBMT risk score increased. HLA matching had no significant impact on relapse (siblings: 24% (21-27); WMUD: 35% (26-44), P=0.11 and MM: 21% (18-24), P=0.81); alemtuzumab T-cell depletion and stem cell source (peripheral blood) were associated with an increased risk. Our findings support the use of WMUD as equivalent alternative to HLA-matched sibling donors for allogeneic HSCT in CLL, and justify the application of EBMT risk score in this disease.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1476-5551
|
| pubmed:author |
pubmed-author:BoogaertsMM,
pubmed-author:BrandRR,
pubmed-author:Chronic Leukemia Working Party of the EBMT,
pubmed-author:DhedinNN,
pubmed-author:DregerPP,
pubmed-author:DuboisVV,
pubmed-author:FinkeJJ,
pubmed-author:KozaVV,
pubmed-author:MichalletMM,
pubmed-author:MilliganDD,
pubmed-author:MorissetSS,
pubmed-author:NiederwieserDD,
pubmed-author:RussellN HNH,
pubmed-author:RuutuTT,
pubmed-author:SobhMM,
pubmed-author:VerdonckLL,
pubmed-author:VindelovLL,
pubmed-author:VitekAA,
pubmed-author:de WitteTT,
pubmed-author:van BiezenAA
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1725-31
|
| pubmed:meshHeading |
pubmed-meshheading:20703257-Adult,
pubmed-meshheading:20703257-Aged,
pubmed-meshheading:20703257-Aged, 80 and over,
pubmed-meshheading:20703257-Female,
pubmed-meshheading:20703257-Follow-Up Studies,
pubmed-meshheading:20703257-Graft vs Host Disease,
pubmed-meshheading:20703257-HLA Antigens,
pubmed-meshheading:20703257-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:20703257-Histocompatibility Testing,
pubmed-meshheading:20703257-Humans,
pubmed-meshheading:20703257-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:20703257-Male,
pubmed-meshheading:20703257-Middle Aged,
pubmed-meshheading:20703257-Registries,
pubmed-meshheading:20703257-Retrospective Studies,
pubmed-meshheading:20703257-Siblings,
pubmed-meshheading:20703257-Survival Rate,
pubmed-meshheading:20703257-Transplantation, Homologous,
pubmed-meshheading:20703257-Treatment Outcome
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry.
|
| pubmed:affiliation |
Department of Hematology, Edouard Herriot Hospital, Lyon, France. mauricette.michallet@chu-lyon.fr
|
| pubmed:publicationType |
Journal Article,
Multicenter Study
|